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Abstract: High doses of intravenous iron have a role in the treatment of a number of clinical 
situations associated with iron deficiency, iron deficiency anemia, and blood loss. In the presence 
of functioning erythropoiesis, iron supplementation alone may be adequate to replenish iron 
stores and restore blood loss. Where hormone replacement with an erythropoiesis-stimulating 
agent is required, iron adequacy will optimize treatment. Intravenous iron offers a rapid means 
of iron repletion and is superior to oral iron in many circumstances, especially in the presence 
of anemia of chronic disease, where it appears to overcome the block to absorption of iron from 
the gastrointestinal tract and immobilization of stored iron. The clinical situations where high 
doses of iron are commonly required are reviewed. These include nondialysis-dependent chronic 
kidney disease, inflammatory bowel disease, obstetrics, menorrhagia, and anemia associated 
with cancer and its treatment. The literature indicates that high doses of iron are required, with 
levels of 1500 mg in nondialysis-dependent chronic kidney disease and up to 3600 mg in inflam-
matory bowel disease. New formulations of intravenous iron have recently been introduced 
that allow clinicians to administer high doses of iron in a single administration. Ferumoxytol 
is available in the US, has a maximum dose of 510 mg iron in a single administration, but is 
limited to use in chronic kidney disease. Ferric carboxymaltose can be rapidly administered in 
doses of 15 mg/kg body weight, up to a ceiling dose of 1000 mg. A test dose is not required, 
and it can be used more widely across a spectrum of iron deficiency and iron deficiency anemia 
indications. The latest introduction is iron isomaltoside 1000. Again, a test dose is not required, 
and it can be delivered rapidly as an infusion (in an hour), allowing even higher doses of iron to 
be administered in a single infusion, ie, 20 mg/kg body weight with no ceiling. This will allow 
clinicians to achieve high-dose repletion more frequently as a single administration. Treatment 
options for iron repletion have taken a major leap forward in the past two years, especially to 
meet the demand for high doses given as a single administration.
Keywords: iron isomaltoside 1000, intravenous iron, iron deficiency anemia, iron deficiency, 
high dose, single dose, erythropoiesis
Introduction
Iron has an essential role in human physiology, albeit the total amount in a healthy 
individual is only approximately 3 grams. The balance of iron in the body broadly 
reflects three dynamics, ie, intake, losses, and metabolic demands. Intake will relate 
to the iron content in food, the volume ingested, and the ability to absorb iron from 
the digestive tract. This may be impaired due to pathology in the gastrointestinal 
tract or comorbidity (eg, a chronic inflammatory condition) resulting in expression 
of the regulatory peptide, hepcidin, which will block iron absorption.1 Loss may be Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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a result of acute trauma or through continual chronic blood 
loss from the gastrointestinal, urinary, or respiratory tract, 
or be associated with renal replacement (hemodialysis) 
in chronic kidney disease.2 Increased demand occurs in 
infancy and childhood, pregnancy, and during use of an 
erythropoiesis-stimulating agent (ESA).3 Stimulation of 
erythropoiesis using an ESA can result in functional iron 
deficiency where the demand for iron increases but cannot 
be met from existing iron stores.4 This may be because of 
low iron store levels (absolute iron deficiency) or limited 
by iron release from storage depots.4
Historically, the oral route of administration was given 
much attention, but the effectiveness of oral formulations is 
compromised by poor absorption, poor compliance, side effects 
(up to 56%), and discontinuation of treatment (19%).5
The challenge of treating iron deficiency is related to the 
toxicity of iron in its elemental state, the required dose, and 
desired rate of repletion. Early parenteral formulations, now 
withdrawn in many countries, were associated with untoward 
effects that limited their use.6 These were surpassed with the 
introduction of iron sucrose and modified formulations of iron 
dextran (and ferric gluconate complex in some countries).7–9 
These formulations had much improved safety profiles and 
lower rates of adverse events. The next inevitable challenge 
was to address the issue of eliminating the need for a test 
dose and being able to administer larger amounts of iron in 
a shorter period of time, thereby potentially improving the 
convenience of treatment.
Three new intravenous iron preparations have recently 
been introduced offering higher single-dose options. None 
of these preparations require a test dose, and all can be 
delivered rapidly. Ferumoxytol (AMAG Pharmaceuticals 
Inc,   Cambridge, MA) is approved for the sole indication of 
adult iron deficiency anemia associated with chronic kidney 
disease. Up to 510 mg iron can be delivered in a single dose.10 
Ferric carboxymaltose (Vifor Pharma, Switzerland) has been 
introduced for intravenous iron supplementation, allowing 
doses of 15 mg/kg body weight (up to a maximum dose of 
1000 mg) to be delivered in a single administration.11 Sub-
sequently, iron isomaltoside 1000 (Pharmacosmos, Holbaek, 
Denmark) has been approved for marketing in Europe, and 
allows higher maximum doses in a single infusion at up to 
20 mg/kg body weight.12
This review highlights the clinical situations where the 
requirements for high dose iron repletion are particularly 
relevant, and considers the practicalities associated with 
treatment. The focus is on iron isomaltoside 1000 and ferric 
carboxymaltose because the use of ferumoxytol is limited 
to patients with chronic kidney disease and geographically 
is available only in the US.
Methods
Literature (database) searches were undertaken and focused on 
guidelines for the diagnosis and treatment of iron   deficiency, 
iron deficiency anemia, and anemia of chronic disease to 
identify the indications for which intravenous iron supple-
mentation is a suggested therapy. Searches were undertaken 
to identify clinical studies investigating the role of intravenous 
iron in treating iron deficiency, iron deficiency anemia, and 
anemia of chronic disease to provide further insights into these 
conditions and the clinical circumstances in which high-dose 
intravenous iron administration would be appropriate. This 
search included papers reporting studies undertaken with 
the new preparations. The dosing parameters and product 
specifications from the manufacturers’ summaries of product 
characteristics were inspected so that comment could be made 
on the appropriateness of the two formulations for use across 
a range of indications. Epidemiological survey data were used 
to establish mean population weights for adults by gender for 
Europe and the US.
Results
Firstly, it is important to consider the implications of deliver-
ing iron as a single high-dose intravenous iron supplement as 
opposed to more frequent small-dose administrations.
Infrequent high-dose administrations of intravenous iron 
reduce the frequency of hospital or clinic visits, thereby causing 
less disruption to patients’ lifestyle, especially if working.13,14 
The overall time spent attending a hospital or clinic can be 
reduced. This is likely to be more convenient for both patients 
and health care professionals and to improve patient compli-
ance.14 Such high-dose administrations have been shown to 
reduce waiting lists (by increasing patient throughput).13 Travel 
costs are reduced, which may   benefit patients, the health care 
economy, and the insurance company.13
From a practical clinical perspective, target hemoglobin 
and ferritin levels may be achieved more rapidly, allowing 
hematinic levels to achieve stability earlier than when using 
multiple small doses, which can be assessed when taking ane-
mia management decisions.13 Reduced frequency of venous 
access should reduce the risk of infection and preserve veins 
for future access. A further major potential clinical benefit is 
that high doses of intravenous iron appear to overcome the 
block caused by hepcidin in patients with anemia of chronic 
disease.1,15 This may be highly significant, allowing treatment 
of anemia in patients with inflammatory conditions.Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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Nondialysis-dependent phase  
of chronic kidney disease
The treatment of anemia associated with chronic kidney 
disease has been transformed since ESAs were introduced. 
Prior to the availability of ESAs, the administration of blood 
transfusions to address anemia associated with chronic kidney 
disease was commonplace. This practice was inconvenient, 
costly (albeit blood costs are “lost” in some health economies), 
and jeopardized the prospects of finding a matching organ for 
transplantation.16 Guidelines indicate that blood transfusions, 
especially for individuals in whom renal   transplantation is an 
option, should be avoided if possible.17
Managing anemia of chronic kidney disease as the disease 
progresses improves the prognosis.18 In the predialysis phase 
(low clearance, nondialysis-dependent) hemoglobin adequacy 
may be sustained with iron supplementation alone, albeit most 
patients will ultimately progress to requiring an ESA.19
It is during this low clearance, nondialysis-dependent 
phase of the disease that patients benefit from high doses of 
intravenous iron. Using the Ganzoni formula, a suitable intra-
venous iron dose can be calculated.11,12,20 Infrequent high-dose 
intravenous iron supplementation will sustain iron adequacy, 
whilst avoiding the need to attend the renal department solely to 
receive iron supplementation, with intervals between repeated 
administrations of up to a year or more.21 This can help preserve 
lifestyle and employment as the disease progresses.
Before an ESA is commenced, iron status should be opti-
mized to avoid functional iron deficiency. This again may be 
achieved by administering a single high dose of intravenous 
iron. The benefit of a single dose, compared with adminis-
tering a number of smaller doses, is that iron metabolism 
stability is achieved more rapidly. The use of frequent smaller 
doses of intravenous iron (once or twice a week) will take 
days or weeks longer to administer the required dose, and then 
a further three weeks from the final dose to achieve stable 
conditions when hematinic levels can be confidently assessed, 
making anemia management more difficult.21 Iron require-
ments of 1000–1500 mg or higher are likely to be required 
to achieve target ferritin and hemoglobin levels.21
For patients subsequently electing to have chronic ambu-
latory peritoneal dialysis as their mode of renal replacement, 
high-dose intravenous iron supplementation is often preferred 
because this continues to obviate the need for frequent hospi-
tal attendance to receive intravenous iron supplementation.
Inflammatory bowel disease
Anemia occurs in an estimated one-third of patients with 
inflammatory bowel disease, which can have a profound 
impact on patient quality of life.22 Anemia associated with 
inflammatory bowel disease commonly reflects a mixed 
etiology of iron deficiency anemia and anemia of chronic 
disease.22 It is suggested that treatment should be considered 
for all patients with a hemoglobin level below normal.23 The 
international guidelines suggest that anemic patients will 
rarely have an iron deficit of less than 1000 mg of iron.23 
These guidelines suggest using transferrin saturation levels 
to monitor intravenous iron treatment. They suggest that 
iron administration may be continued until a limit of 50% 
transferrin saturation is observed. High doses of intravenous 
iron, up to 3600 mg (administered as multiple small doses), 
have been administered to patients with inflammatory bowel 
disease but without liver damage or iron overload, which 
is unlikely to occur because of ongoing blood loss in these 
patients.23 Intestinal bleeding (visible or occult) is associated 
with inflammatory bowel disease, and may be considered as 
a consistent clinical feature.23
The international guidelines indicate that the preferred 
route for iron supplementation is intravenous.23 Intravenous 
iron is more effective, better tolerated, and improves qual-
ity of life to a greater extent than oral iron supplements.23 
Clinical studies indicate a faster and prolonged response with 
intravenous iron.23 In addition to oral iron not being able to 
compensate for ongoing blood loss, studies in animal models 
of inflammatory bowel disease consistently show an increase 
in oxidative stress, disease activity, intestinal inflammation, 
and also the potential for the development of colorectal 
cancer.23 Other studies suggest that nutritional iron may be 
an exogenous promoter for the onset of colitis.
It should be recognized that high doses of intravenous iron 
can overcome the hepcidin-mediated block of iron absorp-
tion associated with anemia of chronic disease and also the 
blocked mobilization of iron stores.15 Success with intrave-
nous iron alone can be achieved in 70%–80% of patients 
with anemia of chronic disease.23 The concomitant use of 
intravenous iron and an ESA achieves optimal hemoglobin 
levels in almost all patients.23
The goals of anemia therapy are to increase the hemoglo-
bin, serum ferritin, and transferrin saturation above the lower 
threshold of normal, to prevent the hemoglobin level falling 
below normal, to avoid the need for a blood transfusion, and 
to relieve symptoms associated with anemia whilst improving 
quality of life. The hemoglobin improvement goal is 20 g/L 
or becoming normal in four weeks.23
It is suggested that absolute indications for using intra-
venous iron include a hemoglobin level below 100 g/L, 
intolerance or suboptimal response to oral iron, severe intes-Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
54
Gozzard
tinal disease activity, concomitant use of ESAs, or patient 
preference.23
Obstetrics
During pregnancy, iron requirements increase from 
1.5–2.0 mg/day to 5–7 mg/day.24 Without adequate stores, and 
with suboptimal intake, iron deficiency anemia may prevail. 
Guidelines suggest that low hemoglobin levels (below 85 g/L) 
increase the risk of poor fetal outcomes (low birth rate,   preterm 
delivery).25
Serum ferritin levels should be used to investigate 
adequacy of iron stores which are considered low if below 
30 µg/L.25 Low iron stores can be readily depleted with blood 
loss at delivery, which may adversely impact the mother’s 
levels of fatigue and energy and therefore ability to care for 
the neonate. This may result in a prolonged stay in hospital.26 
If uncorrected, this may have implications for the baby if 
breastfed because, in the medium to long term, the baby will 
not receive adequate amounts of iron.
Postpartum hemorrhage is a major contributor to maternal 
mortality and morbidity.27 A recent analysis of trends indi-
cates that there is a rise in incidence and severity. Cesarean 
section delivery is associated with higher volume blood 
loss, with 1%–3% of patients losing more than 1000 mL. 
There is a concomitant increase in blood transfusions to treat 
  postpartum hemorrhage.27
Low antenatal hemoglobin concentrations (and especially 
iron deficiency) are a risk factor for postpartum hemorrhage 
and severity of hemorrhage.28 Intravenous iron can be used 
in the antenatal period to correct iron deficiency anemia and 
hemoglobin levels prior to delivery seeking to reduce the risk 
of hemorrhage and need for peripartum blood transfusions.29
In the peripartum period (0–6 months), up to 13% of 
mothers are iron-deficient and 10% are anemic.30 Oral supple-
mentation produces a slow and often suboptimal response. 
Intravenous iron is a safe alternative, reducing the need and 
volume of blood transfusions.29,31 Intravenous iron therapy 
is associated with a significant increase in iron stores and 
hemoglobin levels in this patient group.31
Studies undertaken to evaluate the response to parenteral 
iron administration during pregnancy and in the peripartum 
period indicate that high dose requirements (up to 1600 mg) 
may be required.29,32 The use of a single high-dose administra-
tion of iron was found to be beneficial in antenatal intravenous 
iron supplementation. Compliance can be an issue in patients 
prescribed smaller and more frequent doses of intravenous 
iron. Only 7% of patients commencing a regimen of mul-
tidose intravenous iron sucrose supplementation completed 
the prescribed course of treatment.14 The majority of patients 
(61%) received fewer than five doses, having failed to return 
to the hospital for their infusions. This compared with 100% 
compliance for a high-dose infusion regimen.14
Heavy uterine bleeding
Heavy menstrual bleeding is a common cause of iron 
deficiency anemia in the developed world. Menorrhagia 
is associated with heavy cyclical menstrual bleeding, with 
the loss of 80 mL or more of blood per cycle.33,34 The loss 
of blood in a year would approximate one liter, equivalent 
to 1000–1500 mg of iron per year. Anemia in women with 
menorrhagia is often untreated or inadequately treated.35 
In several updates on the management of menorrhagia, the 
treatment of iron deficiency or iron deficiency anemia is not 
explicitly addressed.34,36–38
Studies indicate that women with heavy uterine bleeding 
have a high requirement for blood transfusions and have 
higher associated hospital costs and reduced quality of life.35 
Iron supplementation to correct iron deficiency and iron 
deficiency anemia in women with menorrhagia can avoid 
blood transfusions in all but those with highly compromised 
hemoglobin levels. Oral iron is unlikely to keep pace with 
iron losses.39,40
In two studies, the effectiveness of intravenous iron 
supplementation has been compared with oral iron in women 
with iron deficiency anemia associated with menorrhagia and 
heavy uterine bleeding.39,40 In both studies, intravenous iron 
was more effective than oral iron, achieving significantly 
higher increases in hemoglobin levels and reaching target 
hemoglobin levels. In a study undertaken by Kim et al, 
the improvement in ferritin levels was highly notable.39 
In another study by Van Wyck et al, patients treated with fer-
ric carboxymaltose reported greater gains in vitality, physical 
function, and improvements in symptoms of fatigue.40 In this 
latter paper, patients received 1000 mg of intravenous iron or 
more (repeated doses) and in the former multiples of 200 mg 
(iron sucrose) three times a week until the total calculated 
repletion dose was achieved. High-dose intravenous iron 
supplementation appears to be highly effective in correcting 
iron deficiency and iron deficiency anemia in women with 
menorrhagia.40
Anemia associated with cancer  
and its treatment
An ESA plus intravenous iron can be used to address anemia 
caused by cancer treatment and can replace the use of blood 
transfusions. The European Organisation for Research and Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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Treatment of Cancer (EORTC) guidelines recognize that 
treating anemia in cancer patients improves their quality 
of life and reduces the requirement for emergency blood 
transfusions which offer only temporary symptom relief 
whilst having a number of associated risks. They recom-
mend early initiation of treatment (at a hemoglobin level 
of 90–110 g/L) with continuation to sustain hemoglobin 
levels #120–130 g/L for patients showing symptomatic 
improvement.41 Optimal improvements in energy, activity, 
and quality of life occur when hemoglobin levels increase 
from 110 g/L to 130 g/L.42
Cancer may be associated with anemia of chronic 
disease.43 It is postulated that cancer patients, with iron-
restricted erythropoiesis, have iron in their stores which is 
not   accessible for erythropoiesis.44 The access to stored iron 
may be inhibited by the upregulation of hepcidin through 
inactivation of ferroportin, the major carrier of iron.44 This 
mechanism appears to operate in other conditions associated 
with anemia of chronic disease.
There are concerns that intravenous iron is underused in 
oncology patients. Appropriate use improves the response 
to ESAs, reducing doses and costs, whilst improving their 
effectiveness in elevating hemoglobin levels and over-
coming anemia of chronic disease.44–47 Bastit et al have 
shown that administration of intravenous iron significantly 
improves hemoglobin levels, hematopoietic response, 
and time to reach target hemoglobin levels when com-
pared with oral iron administration, and has also shown 
a statistically significant reduction in administered blood 
transfusions.48
A study by Pedrazzoli et al investigated the use of either 
an ESA plus intravenous iron or an ESA alone in patients 
with solid tumors undergoing chemotherapy, who were iron-
replete but anemic (excluding patients with absolute or func-
tional iron deficiency). There were statistically significant 
improvements in hemoglobin and hematopoietic responses in 
the intravenous iron group.49 These outcomes echo those of 
Henry et al, in which the response rate was 73% for patients 
receiving an ESA plus intravenous iron compared with 41% 
for an ESA alone.47
Nonresponders in the Pedrazzoli study (after four weeks) 
were given double the dose of ESA. This resulted in a 68.2% 
response in those receiving intravenous iron compared with 
32% in those not receiving intravenous iron (P = 0.019).49
In the US, the Food and Drug Administration limits the 
use of an ESA agent to promote erythropoiesis in oncol-
ogy patients to a ceiling of $100 g/L hemoglobin.50 This 
reflects concerns that hemoglobin levels above 100 g/L may 
adversely impact cancer progression.51 There is evidence 
from the renal arena to suggest that cancer progression may 
be caused by a direct effect of ESAs on the tumor and not 
the hemoglobin level.52 It is interesting to reflect on the focus 
of use of ESAs in the treatment of anemia associated with 
cancer without a parallel interest in the requirement for iron 
adequacy as a substrate for erythropoiesis.
In anemia associated with chronic kidney disease, both 
guidelines and clinical practice highlight the importance 
of iron adequacy when administering ESAs to prevent 
  absolute or functional deficiency. The knowledge gained in 
the chronic kidney disease arena has not been heeded in the 
oncology arena, although several studies have concluded 
that the use of intravenous iron, as a supplement to ESAs, 
improves the efficacy of ESAs and can result in reduced 
dose requirements.45
The significance of intravenous iron, recognition of the 
possible coexistence of anemia of chronic disease, and the 
potential implications of iron deficiency and iron deficiency 
anemia in oncology patients, is now reflected in revisions of 
guidelines for the treatment of anemia associated with cancer. 
UK National Institute for Health and Clinical Excellence 
guidelines state that “erythropoietin analogues are recom-
mended in combination with intravenous iron”.53 EORTC 
guidelines also indicate that whilst there is no evidence that 
oral iron supplements increase the response to ESAs, there is 
evidence of a better response to ESAs with intravenous iron. 
The guidelines recommend use in absolute and functional 
iron deficiency.54 The American Society of Hematology and 
American Society of Clinical Oncology recommend moni-
toring iron parameters and correcting suboptimal levels in 
patients who are receiving ESA therapy.55
An insight into the required levels of intravenous iron 
repletion can be taken from the review of studies evaluat-
ing intravenous iron and ESAs in oncology.44 Doses are 
commonly up to 1000 mg or higher when administered as 
a total dose infusion and are calculated using the Ganzoni 
formula.20,44,47
Discussion
Iron deficiency anemia and its precursor, iron deficiency, 
are associated with a number of clinical conditions. In many 
of these conditions, a blood transfusion has been the tradi-
tional approach to addressing iron deficiency anemia or iron 
  deficiency, especially if oral iron has failed, is inappropriate, 
or a rapid resolution is required.
The development and introduction of safer intravenous 
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has led to a re-evaluation of the role of intravenous iron, and 
provided clinicians with the facility to explore and develop 
the clinical use of these products. There is now a substantial 
evidence base of clinical papers that support the safety and 
efficacy of intravenous iron in a broad spectrum of clinical 
situations associated with iron deficiency and iron deficiency 
anemia. Studies comparing intravenous iron with oral iron, 
in addition to demonstrating equal or superior efficacy, 
often reflect on the more rapid repletion of iron stores and 
quicker elevation of hemoglobin levels.23,29,40,48 Furthermore, 
they highlight inadequacies of oral iron (side effects, poor 
  compliance, poor absorption) and, in patients with continual 
blood loss, the inability to keep pace with the loss and sustain 
iron adequacy.23,29,40 A common requirement across the range 
of clinical situations is the need for higher and less frequent 
doses to achieve optimal clinical outcomes. The drivers of this 
practice also include overall cost reduction, improved patient 
convenience, improved compliance, preservation of venous 
access, and reduced blood transfusions (See Table 1).13,14,44,48
The introduction of ferric carboxymaltose and iron 
isomaltoside 1000, which do not require a test dose, and 
can be administered more rapidly and in higher doses, add a 
further dimension to the clinical proposition of intravenous 
iron. Furthermore, they distance intravenous iron further 
from oral iron as a source of iron repletion, especially as it 
is recognized that intravenous iron, and not oral iron, can 
overcome anemia of chronic disease.15
Much of the accumulated knowledge gained from the 
extensive use of intravenous iron in treating iron deficiency 
anemia and iron deficiency associated with chronic kidney 
disease has only slowly migrated to other disciplines. Thus, 
while blood transfusions for chronic kidney disease patients 
have virtually been eliminated, this is not the case in other 
clinical situations. The vast majority of chronic kidney 
disease patients progress to receive intravenous iron plus 
an ESA. Absolute and functional iron deficiency are well 
understood by renal clinicians and, because of this, guidelines 
recommend that iron adequacy be achieved prior to com-
mencing an ESA. In low clearance (nondialysis-  dependent) 
and chronic ambulatory peritoneal dialysis patients, and when 
undertaking iron repletion ahead of initiating ESA treatment, 
high-dose supplementation is common practice. Indeed, in 
renal medicine, high-dose intravenous iron alone can delay 
the need for ESA treatment in the low clearance (nondialysis-
dependent) chronic kidney disease population.13,19
Iron repletion prior to commencing an ESA will improve 
the efficacy of treatment, often resulting in lower doses, with 
accruing cost savings. This practice has been slow to transfer 
into other arenas where ESAs have been used, often in much 
higher dosage regimens, especially in oncology. As Auerbach 
indicates, in oncology patients blood transfusion rates have 
declined by only 50%, whereas in patients with chronic kidney 
disease the elimination of blood transfusions has been almost 
total.44 The role of intravenous iron and the need to establish 
adequate iron repletion prior to commencing an ESA is now 
explicit in the various guidelines for diseases where iron defi-
ciency and iron deficiency anemia are implicated.47,49,53–55
The recognition that anemia of chronic disease can be 
overcome using intravenous iron, and a greater understanding 
of the mechanism behind anemia of chronic disease have also 
encouraged wider intravenous iron use at higher dose levels. 
This may not only account for the success in treating anemia 
associated with chronic kidney disease but also inflammatory 
bowel disease (with or without an ESA) and again may sug-
gest that intravenous iron can have a more profound role in 
patients being treated for cancer. Studies reported by Henry 
et al and Pedrazzoli et al support this role.47,49
Blood loss is apparent in several situations where high-
dose intravenous iron is used. In such situations, robust 
iron stores are needed to sustain erythropoiesis (with or 
without concurrent use of an ESA). This is particularly 
important in inflammatory bowel disease and menorrhagia 
where intravenous iron can sustain iron adequacy and keep 
pace with blood loss. This can avoid or reduce the need for 
blood transfusions. Indeed, prior to surgery, high doses of 
intravenous iron are being used in anticipation of blood loss 
to reduce the transfusion requirement or postsurgically to 
Table 1 Summary of potential benefits of high-dose administra-
tions of intravenous iron
Benefit Reference
Single clinic visit to receive desired 
dose (or reduced clinic visits)
Peebles and Stanley13 
Jenkins14 
Summaries of product 
characteristics11,12
improved patient compliance 
(and convenience)
Peebles and Stanley13 
Jenkins14
Cost reduction Peebles and Stanley13 
Besarab et al4
Preservation of venous access Peebles and Stanley13
Reduction in number and/or volume 
of blood transfusions
Bastit et al48 
Auerbach44
improved erythropoiesis-stimulating 
agents efficiency and/or reduced 
erythropoiesis-stimulating agent dose
Besarab et al4 
Fishbane et al45 
Auerbach et al46 
Henry et al47 
Bastit et al48
improved prospect of transplant 
(by avoiding blood transfusions)
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restore hemoglobin levels. The evidence base and guidelines 
for the role of high-dose intravenous iron are still emerging, 
hence their omission in this review.
The introduction of ferric carboxymaltose and, subse-
quently, iron isomaltoside 1000 are welcome developments. 
These provide intravenous iron in a form that will make it 
easier for clinicians to use and therefore encourage wider 
intravenous iron use across the range of conditions where 
the use of high-dose intravenous iron achieves good clinical 
outcomes.
The required dose of iron can be calculated using the 
Ganzoni formula, which is applicable across the spectrum 
of indications. This takes into account body weight, target 
hemoglobin level, and desired iron stores.
The introduction of ferric carboxymaltose has progressed 
intravenous iron repletion by offering high-dose treatment 
rapidly without a test dose. The subsequent introduction of 
iron isomaltoside 1000 may be considered to add to this 
profile by offering the prospect of administering even higher 
doses of intravenous iron in a single administration without 
compromising safety.
In addition to being able to deliver more iron to a patient 
in a single infusion, the use of iron isomaltoside 1000 is 
not constrained by the aluminum or sodium content in its 
formulation. Ferric carboxymaltose contains aluminum (up to 
75 µg/mL) and up to 5.5 mg of sodium per mL which may be 
of concern in dialysis patients and those on sodium-restricted 
diets.11 The frequency of administration is limited to one 
infusion every seven days for both products.
The implications of the maximum iron dose based on 
body weight can be considered by examining doses that can 
be administered based on mean population adult body weights 
by gender in Europe and the US (See Tables 2 and 3).
From these tables it can be seen that, from body weight 
alone, the scope for administering high-dose infusions (above 
1000 mg iron) in a single infusion is higher with iron isomalto-
side 1000 than with ferric carboxymaltose. The tables reveal 
that only women in Europe with a mean body weight of 65.8 kg 
can receive the maximum permitted 15 mg/kg iron dose of fer-
ric carboxymaltose in a single infusion. Patients in the weight 
range 50–67 kg, approximately 33% of the population, may 
receive a dose of 1000 mg (or more) when iron isomaltoside 
1000 is administered; however, only those weighing more 
than 67 kg can receive the maximum 1000 mg dose of ferric 
carboxymaltose.11,12,56 The scope for giving higher doses of 
isomaltoside 1000 is far wider, suggesting that its use may 
avoid the need for two or more infusions and two or more visits 
to a hospital to receive the required calculated dose.
The relevance of these dose constraints should be consid-
ered in the context of the spectrum of dose levels detailed in 
the clinical conditions outlined. The need to administer high 
doses of intravenous iron to achieve desired target hemoglo-
bin and ferritin levels is illustrated in the various potential 
clinical situations. In various studies, high doses are cited 
with ranges up to 1500 mg of iron for nondialysis-dependent 
chronic kidney disease, 3600 mg in inflammatory bowel 
disease, 1600 mg in obstetrics, 2000 mg in menorrhagia, 
and 3000 mg in cancer (See Table 4).21,23,29,40,46
Table 2 Maximum permitted iron dose based on mean body weight: european population
Male, mean adult weight 78.9 kg Female, mean adult weight 65.8 kg
Maximum dose 
based on body 
weight
Maximum dose 
allowed according to 
SPC11,12
Maximum dose 
based on body 
weight
Maximum dose 
allowed according to 
SPC11,12
iron isomaltoside 1000 1578 mg* 1578 mg iron isomaltoside 1000 1316 mg* 1316 mg
Ferric carboxymaltose 1183 mg† 1000 mg Ferric carboxymaltose 987 mg† 987 mg
Notes: †based on 15 mg/kg body weight; *based on 20 mg/kg body weight. Source of population data.56
Abbreviation: SPC, summary of product characteristics.
Table 3 Maximum permitted iron dose based on mean body weight: US population
Male, mean adult weight, 86.8 kg Female, mean adult weight, 74.7 kg
Maximum dose 
based on body 
weight
Maximum dose 
allowed according to 
SPC11,12
Maximum dose 
based on body 
weight
Maximum dose 
allowed according to 
SPC11,12
iron isomaltoside 1000 1736 mg* 1736 mg iron isomaltoside 1000 1494 mg* 1494 mg
Ferric carboxymaltose 1302 mg† 1000 mg Ferric carboxymaltose 1121 mg† 1000 mg
Notes: †Based on 15 mg/kg body weight; *based on 20 mg/kg body weight; Source of population data.57
Abbreviation: SPC, summary of product characteristics.Drug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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The need to administer doses of 1000 mg or more is 
not uncommon. In studies published on the use of ferric 
carboxymaltose, the need for more than a single infusion to 
achieve the required calculated dose to be administered is 
explicit. In inflammatory bowel disease, the authors indicate 
that ferric carboxymaltose was administered at “1-week 
intervals until the patients’ calculated total iron deficit was 
reached”.60 In a study reporting on the safety and tolerability 
of ferric carboxymaltose across a range of indications, 94% 
of patients received a total calculated dose of 1000 mg or 
more.32 In a study investigating the efficacy of ferric car-
boxymaltose in the treatment of heavy uterine bleeding, the 
authors indicate that five patients received a single infusion, 
197 patients received two infusions, and 28 received three 
infusions (n = 230). The mean dose was 1568 mg, and 97.8% 
received total doses that exceeded 1000 mg, the equivalent 
of iron in 5 units of blood.40
The need to be able to deliver high doses of iron in a num-
ber of clinical circumstances is unequivocal. Reducing the 
frequency of administrations will improve compliance and 
the burden of hospital visits to receive iron administrations.14 
This is likely to be more convenient for both patients and 
health care professionals. Financial savings should accrue 
from a reduction in visits, reduced travel and transportation 
costs, use of giving sets, nursing time (preparation, setting 
up, and monitoring infusion delivery), and pharmacy prepara-
tion time. Further savings should accrue directly by avoiding 
functional iron deficiency when ESAs are being administered, 
thereby optimizing ESA use, and in some   circumstances 
allowing a reduction in ESA dose levels.4,45
In this review we have not considered the relative adverse 
event profiles of the two preparations. A recent study in the 
US suggests that serious adverse events associated with 
intravenous iron therapy are rare.61,62
Whilst there is a difference in carbohydrate composition 
and molecular structure between iron isomaltoside 1000 and 
ferric carboxymaltose, the summaries of product characteris-
tics suggest that the type and severity of any adverse events 
are likely to be similar.11,12 Real world data reporting of actual 
adverse events as the products are adopted in practice and 
future studies may reveal differences.
Conclusion
A review of clinical situations in which intravenous iron 
administration is appropriate reveals that high doses of iron 
supplementation are commonly required to optimize the 
management of iron deficiency and iron deficiency anemia 
either alone or concomitantly with an ESA. The benefits 
of intravenous compared with oral iron repletion are high-
lighted, especially in circumstances where there is chronic 
ongoing blood loss and where anemia of chronic disease is 
implicated.
The administration of high doses of iron can reduce the 
need for frequent hospital visits. This is more convenient 
for both patients and health care professionals. There are a 
number of cost savings associated with reduced frequency 
of administrations, including hospital visits to receive iron 
infusions. The number of infusions required to deliver the 
desired dose requirements may affect compliance, and 
therefore likelihood of achieving the required repletion 
and the speed of repletion. In many circumstances, the use 
of these products will directly result in a reduced demand 
for blood   transfusions. This will help to preserve blood 
  supplies and lessen the exposure to the risks associated with 
blood   transfusions. Such accumulated savings may fully, or 
  partially, offset the cost of these new medications.
The introduction of new intravenous iron formulations, 
especially in quick succession, suggests that existing options 
for treatment were not optimal. There has now been major 
progress in addressing these shortcomings because the 
introduction of ferumoxytol and ferric carboxymaltose real-
ized the aim of not requiring a test dose whilst offering the 
Table 4 Summary of comparative profiles of iron isomaltoside 1000 and ferric carboxymaltose11,12,58,59
Ferric carboxymaltose  Iron isomaltoside 1000
Maximum dose per kg body weight 15 mg iron/kg body weight 20 mg iron/kg body weight
Maximum dose in a single administration 1000 mg 20 mg iron/kg body weight 
Minimum body weight for 1000 mg dose 67 kg 50 kg
Speed of administration ,500 mg in 6 minutes 
500–1000 mg in 15 minutes
0–5 mg/kg in 15 minutes 
6–10 mg/kg in 30 minutes 
11–20 mg/kg in 60 minutes
Test dose required No No
Short chain carbohydrate structure No 
Branched 
polysaccharides
Yes 
Unbranched linear 
oligosaccharidesDrug Design, Development and Therapy 2011:5 submit your manuscript | www.dovepress.com
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ability to administer far higher single doses of iron rapidly. 
The ceiling imposed on the size of a single dose of ferric 
carboxymaltose (15 mg/kg body weight up to a ceiling of 
1000 mg) has been surpassed by the introduction of iron 
isomaltoside 1000 where the scope for a single infusion has 
been increased to 20 mg/kg body weight, without a ceiling, 
within an hour and without a test dose.
Recognition of the prevalence of iron deficiency and iron 
deficiency anemia and its association with a wide range of 
clinical situations, the understanding of the mechanism of 
anemia of chronic disease, and how this may be successfully 
addressed with intravenous iron, and the emerging prospect 
of iron being used to avoid or reduce the demand for blood 
transfusions, highlight the growing need for intravenous 
iron in higher single doses. Treatment options for iron defi-
ciency anemia have taken a major leap forward in the past 
two years.
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